Control | Treatment | p Value | |
FEV1% decline during study period | −8.3% | −10.4% | 0.940 |
BMI z-score change | −0.09±0.15 | −0.003±0.08 | 0.603 |
Chest x-ray score change | +2.10±0.51 | +2.00±0.50 | 0.885 |
Inflammatory parameters | |||
Immunoglobulin G | 9.84±3.54 | 8.66±3.82 | 0.105 |
Leucocytes (×109/l) | 9.17±2.88 | 8.67±2.68 | 0.499 |
Proportion of patients with CRP >10 mg/l during study | 16.1% | 14.7% | 0.874 |
Adverse events | 45.2% | 50.0% | 0.696 |
Cough and/or increased sputum production | 38.7% | 23.5% | 0.185 |
Gastrointestinal | 9.7% | 20.6% | 0.192 |
Other (headache, erythema, fatigue, incontinence) | 0.0% | 14.7% | 0.054 |
BMI, body mass index; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s.